Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
COVID-19
COVID-19 Update
Evaluate Vantage COVID-19 Report
COVID-19 Stories from Evaluate Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
EvaluatePharma
Evaluate Omnium
Japan Drug Forecasts
European Drug Forecasts
Epi Analyzer
Evaluate Custom Solutions
Evaluate Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Evaluate Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Durata Therapeutics
August 14, 2015
Interview – Motif seizes on antibiotic renaissance
October 07, 2014
Takeout of Durata shows antibiotics investment can pay dividends
August 08, 2014
Price the spotlight for newly launched antibiotics
July 21, 2014
Event – Medicines Company hopes to reverse fortune with Orbactiv
June 23, 2014
Unrestricted label means Sivextro can start to challenge Zyvox
May 27, 2014
FDA antibiotics programme yields first approval in Durata’s Dalvance
April 01, 2014
New antibiotics ace panel, but will need to differentiate themselves
March 20, 2014
Upcoming events: US panels to discuss new antibiotics and Mannkind’s Afrezza
February 21, 2013
Choice newcomers piggyback on 2012’s IPO successes
November 21, 2012
2011 IPO vintage goes sour
September 28, 2012
St Jude banks on innovation to see it through tough times for medtech
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
December 10, 2020
Evaluate Vantage 2021 Preview
July 29, 2020
Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020
Editor's Picks
December 10, 2020
What the coming year might hold for biopharma
December 11, 2020
Covid-19 vaccine developers remind the world that setbacks happen
December 09, 2020
Astrazeneca’s vaccine looks increasingly like an also-ran
November 09, 2020
Pfizer and Biontech snatch first Covid vaccine victory
December 01, 2020
The promise and the perils of antigen testing
